Stemline Therapeutics

Insilico Medicine, Menarini sign second $500M+ cancer drug deal

Their second exclusive, global in-licensing covers a second small molecule inhibitor, this time targeting what they described as a variety of solid tumors.

Conor Hale Jan 10, 2025 9:30am

Insilico nabs $500M+ biobucks deal for preclinical cancer asset

Jan 4, 2024 10:00am

Gilead grabs MacroGenics blood-cancer focused bispecific in 176B license-option deal

Gilead offers $1.76B for option to MacroGenics' bispecific

Oct 17, 2022 11:00am

Stemline licenses RET inhibitor from U.K. cancer group

Mar 11, 2019 9:53am

Stemline admits it learned of patient death before $45M stock offering

Feb 3, 2017 4:38am